Skip to main content Skip to main navigation menu Skip to site footer

Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus

  • Cahyo Edi Baskoro ,
  • Ni Made Renny Anggreni Rena ,


Introduction: Multiple myeloma is the second most common hematological malignancy after non-Hodgkin's lymphoma with a case prevalence in Prof. Dr. I.G.N.G. Ngoerah Hospital for the 2013-2017 period was 4.64% with the most cases occurring in 2017 (33.3%), where 45.8% of multiple myeloma patients were in the age group of 51-60 years old. This study aims to describe a case of multiple myeloma monoclonal gammopathy lambda in a young adult male which is a very rare case.

Case Presentation: 35-year-old male patient whose laboratory and radiological findings supported a diagnosis of multiple myeloma, the right clavicle pain was the primary complaint, and radiological imaging revealed brittle bones. Furthermore, the examination of bone marrow aspiration smear, serum protein electrophoresis, routine hematology, erythrocyte sedimentation rate, clinical chemistry (such as calcium, uric acid, liver function tests, urea and creatinine), and radiological examination, such as the plain X-ray of bone) shows prominent and specific laboratory findings to confirm multiple myeloma.

Conclusion: The diagnosis of multiple myeloma was established with manifestations of bone lesions, serum protein electrophoresis and bone marrow biopsy were carried out for diagnosis based on the International Myeloma Working Group (IMWG) diagnostic criteria. Monitoring after administering six series of primary management of multiple myeloma in patient showed significant improvement from the results of laboratory evaluation, radiology, and bone marrow imaging.


Latar Belakang: Multiple myeloma adalah keganasan hematologis kedua yang paling umum setelah limfoma non-Hodgkin dengan prevalensi kasus di RSUP Prof. Dr. I.G.N.G. Ngoerah periode 2013-2017 adalah 4,64% dengan kasus terbanyak terjadi pada tahun 2017 (33,3%), dimana 45,8% pasien multiple myeloma berada pada kelompok umur 51-60 tahun. Studi ini bertujuan ini untuk mendeskripsikan kasus multiple myeloma monoklonal gamopati lambda pada seorang laki-laki dewasa muda yang merupakan kasus sangat jarang.

Presentasi Kasus: Pasien laki-laki berusia 35 tahun dengan hasil laboratorium dan radiologis mendukung diagnosis multiple myeloma, nyeri klavikula kanan adalah keluhan utama, dan pemeriksaan radiologi menunjukkan tulang rapuh. Selanjutnya pemeriksaan apusan aspirasi sumsum tulang, elektroforesis protein serum, hematologi rutin, laju endap darah, kimia klinik (seperti kalsium, asam urat, tes fungsi hati, ureum, dan kreatinin), dan pemeriksaan radiologis, seperti foto polos X- ray tulang) menunjukkan temuan laboratorium yang menonjol dan spesifik untuk mengkonfirmasi multiple myeloma.

Simpulan: Diagnosis multiple myeloma ditegakkan dengan manifestasi lesi tulang, telah dilakukan pemeriksaan elektroforesis protein serum dan biopsi sumsum tulang untuk penegakan diagnosis berdasarkan kriteria diagnostik International Myeloma Working Group (IMWG). Monitoring setelah pemberian enam seri tatalaksana primer multiple myeloma pada pasien didapatkan perbaikan yang signifikan dari hasil evaluasi laboratorium, radiologis, dan gambaran sumsum tulang.


  2. Jewell S, Xiang Z, Kunthur A, Mehta P. Multiple Myeloma: Updates on Diagnosis and Management. Fed Pract. 2015;32(7):49S-56S.
  3. Landgren O, Kyle RA, Pfeiffer RM, Katzmann JA, Caporaso NE, Hayes RB, et al. Monoclonal gammopathy of undetermined significance (MGUS) consistently precedes multiple myeloma: A prospective study. Blood. 2009;113(22).
  4. Weiss BM, Abadie J, Verma P, Howard RS, Kuehl WM. A monoclonal gammopathy precedes multiple myeloma in most patients. Blood. 2009;113(22).
  5. Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics, 2021. CA Cancer J Clin. 2021;71(1):7–33.
  6. Wijaya KM, Gde Eka Wiratnaya, Setiawan GB. Prevalensi Multiple Myeloma Berdasarkan Umur, Jenis Kelamin Dan Lesi Pada Tulang Di RSUP Prof. Dr. I.G.N.G. Ngoerah/FK Unud Periode 2013-2017. E-Jurnal Med Udayana. 2019;8(4):1–7.
  7. Fairfield H, Falank C, Avery L, Reagan MR. Multiple myeloma in the marrow: pathogenesis and treatments. Ann N Y Acad Sci. 2016;1364(1):32-51.
  8. Gonsalves WI, Gertz MA, Gupta V, Rajkumar SV, Morice WG, Timm MM, et al. Prognostic Significance of Quantifying Circulating Plasma Cells in Multiple Myeloma. Clin Lymphoma Myeloma Leuk. 2014;14.
  9. Drayson M, Tang LX, Drew R, Mead GP, Carr-Smith H, Bradwell AR. Serum free light-chain measurements for identifying and monitoring patients with nonsecretory multiple myeloma. Blood. 2001;97(9).
  10. Rajkumar SV, Dimopoulos MA, Palumbo A, Blade J, Merlini G, Mateos MV, et al. International Myeloma Working Group updated criteria for the diagnosis of multiple myeloma. Lancet Oncol. 2014;15(12):e538–48.
  11. Parving HH, Brenner BM, McMurray JJV, de Zeeuw D, Haffner SM, Solomon SD, et al. Cardiorenal End Points in a Trial of Aliskiren for Type 2 Diabetes. N Engl J Med. 2012;367(23).
  12. Palumbo A, Anderson K. Multiple Myeloma. N Engl J Med. 2011;364:1046-1060.
  13. Bergagsel PL, Kuehl WM. Molecular Pathogenesis and a Consequent Classification of Multiple Myeloma. J Clin Oncol. 2005;23:6333-6338.
  14. Bianchi G, Munshi NC. Pathogenesis beyond the cancer clone(s) in multiple myeloma. Blood. 2015;125:3049-3056.
  15. Bergsagel PL, Stewart AK, Russel J, Fonseca R. Molecular genetic aspects of plasma cell disorders. In: Greer JP, Arber DA, Glader B, List A, Means RT, Paraskevas, Rodgers GM (editors). Wintrobe Clinical Hematology. Thirteen edition. Philadelphia: Lippincott, Williams & Wilkins, 2014.
  16. Shah N, Aiello J, Avigan DE, et al. The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of multiple myeloma. J Immunother Cancer. 2020;8(2):e000734.
  17. Gulla A, Anderson KC. Multiple myeloma: the (r)evolution of current therapy and a glance into the future. Haematologica. 2020;105(10):2358-2367.
  18. Pisano M, Cheng Y, Sun F, et al. Laboratory Mice - A Driving Force in Immunopathology and Immunotherapy Studies of Human Multiple Myeloma. Front Immunol. 2021;12:667054.
  19. Michael TG, Thomas L, Niels A. Plasma cell leukemia: definition, presentation and treatment. Curr Oncol Rep. 2019;21(1):8.
  20. Batuman V. The pathogenesis of acute kidney impairment in patients with multiple myeloma. Adv Chronic Kidney Dis. 2012;19(5):282-286.
  21. Rajkumar SV. Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol. 2022;97(8):1086-1107.
  22. Bernstein ZS, Kim EB, Raje N. Bone Disease in Multiple Myeloma: Biologic and Clinical Implications. Cells. 2022;11(15):2308.
  23. Cho SF, Anderson KC, Tai YT. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy. Front Immunol. 2018;9:1821.
  24. Wedari NLPH, Budayanti NNS, Sukrama IDM, Mayura IPB. Implementation of antinuclear antibodies in autoimmune diagnostic tests: a literature review from immunological aspects. Journal of Clinical Microbiology and Infectious Diseases. 2022;2(2):27-30.
  25. Barwick BG, Gupta VA, Vertino PM, Boise LH. Cell of Origin and Genetic Alterations in the Pathogenesis of Multiple Myeloma. Front Immunol. 2019;10:1121.
  26. Putrawan SNO, Jawi IM, Yasa IWPS, Subawa AAN, Manuaba IBP. Excessive physical exercise caused a decrease in CD4+ and Hematopoietic Stem Cell (HSC) levels in Wistar rats. Bali Med J. 2022;11(3):1456-1460.

How to Cite

Cahyo Edi Baskoro, & Rena, N. M. R. A. (2023). Seorang laki-laki dewasa muda dengan multiple myeloma monoklonal gamopati lambda: sebuah laporan kasus. Intisari Sains Medis, 14(1), 176–182.




Search Panel

Cahyo Edi Baskoro
Google Scholar
ISM Journal

Ni Made Renny Anggreni Rena
Google Scholar
ISM Journal